Hepatitis B market getting heated

Published: 2012-12-12 06:56:00

Updated: 2012-12-12 06:56:00

Competition is about to heat up in the domestic anti-hepatitis drug market as Gilead Sciences’ Viread (tenofovir disoproxil fumarate), which has been launched here from Dec. 1, is expected to expanding its share of the domestic anti-hepatitis B market dominated by BMS’s Baraclude (entecavir).

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK